Table 3. Estimated annual benefits and risks of rotavirus vaccine, France, 2015.

Vaccine coverage scenario	Event	Benefit (prevented RVGE)		Risk (vaccine-induced IS)		Benefit–risk ratio
		Median	2.5th–97.5th percentiles	Median	2.5th–97.5th percentiles	Median	2.5th–97.5th percentiles
Current (Rotarix coverage of 6.7% and RotaTeq coverage of 2.9%)	Hospitalisation	1,074	810–1,378	5.0	3.2– 7.7	214	128–362
	Death	1.4	1.2–1. 6	0.005	0.001–0.015	273	89–1,228
Rotarix coverage reaching 92%	Hospitalisation	10,459	7,702–13,498	47.0	25.1–81.4	221	118–437
	Death	13.7	11.1–15.2	0.05	0.01–0.15	284	86–1,339
RotaTeq coverage reaching 92%	Hospitalisation	10,291	7,901–13,087	49.9	28.7–81.8	206	118–376
	Death	13.3	12.1–14.7	0.05	0.01–0.16	263	84–1,180

IS: intussusception; RVGE: rotavirus gastroenteritis.